Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

In breast cancer cells with HER2 gene amplification, HER2 receptors exist on the cell surface as monomers, homodimers and heterodimers with EGFR/HER3. The therapeutic antibody trastuzumab, an approved therapy for HER2+ breast cancer, cannot block ligand-induced HER2 heterodimers, suggesting it canno...

詳細記述

保存先:
書誌詳細
主要な著者: Ghosh, Ritwik, Narasanna, Archana, Wang, Shizhen Emily, Liu, Shuying, Chakrabarty, Anindita, Balko, Justin M., González-Angulo, Ana María, Mills, Gordon B., Penuel, Elicia, Winslow, John, Sperinde, Jeff, Dua, Rajiv, Pidaparthi, Sailaja, Mukherjee, Ali, Leitzel, Kim, Kostler, Wolfgang J., Lipton, Allan, Bates, Michael, Arteaga, Carlos L.
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3221734/
https://ncbi.nlm.nih.gov/pubmed/21324925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-1872
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料